Gobardhan Paul D, Madsen Eva V E, van Dalen Thijs, Perre Cornelis I, Bongers Vivian
Department of Surgery, Amphia Hospital, Breda, The Netherlands.
Nucl Med Commun. 2012 Jan;33(1):80-3. doi: 10.1097/MNM.0b013e32834cd71f.
Peritumoral and periareolar tracer injection techniques lead to different lymphatic drainage in sentinel lymph node biopsy procedures. In a prospective study, the visualization and identification rates of the ultrasound (US)-guided tracer injection technique for palpable and nonpalpable breast tumors were evaluated.
In 1262 consecutive patients with cT₁₋₂N0 breast cancer, sentinel lymph node biopsy was performed following peritumoral tracer injection. In the case of nonpalpable breast lesions, Tc-99m nanocolloid injections were given using a 7.5 MHz US probe. In the case of ultrasonographically nonvisible microcalcifications, the US-guided injection technique was wire guided.
In 331 patients with nonpalpable breast lesions (26.2%), the lymphoscintigraphic visualization and surgical retrieval rates of axillary sentinel lymph nodes (SLNs) were 98.5 and 99.4%, respectively. For internal mammary (IM) SLNs, these rates were 21.1 and 17.8%, respectively. These rates were similar in patients with palpable and nonpalpable tumors. Axillary metastases were detected in 38.7% of the patients with palpable tumors versus 16.5% of those with nonpalpable tumors (P<0.001), whereas IM metastases were found in 4.8 and 3.0% of patients, respectively (P=0.165).
In nonpalpable breast lesions, the US-guided injection technique is an accurate technique for SLN identification and retrieval. The substantial rates of IM metastases in both palpable and nonpalpable lesions favor a peritumoral tracer injection technique.
在前哨淋巴结活检手术中,瘤周和乳晕周围示踪剂注射技术会导致不同的淋巴引流。在一项前瞻性研究中,评估了超声(US)引导下示踪剂注射技术对可触及和不可触及乳腺肿瘤的可视化和识别率。
对1262例连续的cT₁₋₂N0期乳腺癌患者进行瘤周示踪剂注射后行前哨淋巴结活检。对于不可触及的乳腺病变,使用7.5MHz超声探头注射锝-99m纳米胶体。对于超声不可见的微钙化,采用超声引导下的导丝注射技术。
在331例不可触及乳腺病变患者(26.2%)中,腋窝前哨淋巴结(SLN)的淋巴闪烁显像可视化率和手术取出率分别为98.5%和99.4%。对于内乳(IM)SLN,这些率分别为21.1%和17.8%。可触及和不可触及肿瘤患者的这些率相似。可触及肿瘤患者中38.7%检测到腋窝转移,而不可触及肿瘤患者中为16.5%(P<0.001),而IM转移分别在4.8%和3.0%的患者中发现(P=0.165)。
在不可触及的乳腺病变中,超声引导注射技术是一种准确的SLN识别和取出技术。可触及和不可触及病变中IM转移的相当比例支持瘤周示踪剂注射技术。